Cargando…

Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

Sabatolimab is a novel immunotherapy with immuno‐myeloid activity that targets T‐cell immunoglobulin domain and mucin domain‐3 (TIM‐3) on immune cells and leukemic blasts. It is being evaluated for the treatment of myeloid malignancies in the STIMULUS clinical trial program. The objective of this an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Siyan, Zhang, Na, Rinne, Mikael L., Sun, Haiying, Stein, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681456/ https://www.ncbi.nlm.nih.gov/pubmed/37186155 http://dx.doi.org/10.1002/psp4.12962

Ejemplares similares

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
por: Schwartz, Stephanie, et al.
Publicado: (2022)

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Publicado: (2023)

MBG: Minimizer-based sparse de Bruijn Graph construction
por: Rautiainen, Mikko, et al.
Publicado: (2021)

MBG/ PGA-PCL composite scaffolds provide highly tunable degradation and osteogenic features
por: Li, Jiangfeng, et al.
Publicado: (2021)

Design report of the MBG main bending dipoles for the proton transfer line TT41 of CNGS
por: Schirm, K M
Publicado: (2002)

Genomic and transcriptomic insights into the ecology and metabolism of benthic archaeal cosmopolitan, Thermoprofundales (MBG-D archaea)
por: Zhou, Zhichao, et al.
Publicado: (2018)

Preparation and Biocompatibility of Poly Methyl Methacrylate (PMMA)-Mesoporous Bioactive Glass (MBG) Composite Scaffolds
por: Atkinson, Irina, et al.
Publicado: (2021)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Oral Administration of MBG to Modulate Immune Responses and Suppress OVA-Sensitized Allergy in a Murine Model
por: Wu, Yu-Sheng, et al.
Publicado: (2014)

p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia
por: Man, Na, et al.
Publicado: (2021)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Morelli, Emanuela, et al.
Publicado: (2021)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

P453: NOVEL INSIGHTS INTO MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA USING PRIMARY SAMPLES AND A CLINICALLY RELEVANT PDX MODEL.
por: Aroua, Nesrine, et al.
Publicado: (2023)

Séminaire Bourbaki : exposés 453–470
por: Collective
Publicado: (1976)

Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
por: Liu, Xiaoli, et al.
Publicado: (2023)

Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
por: Baptista, Renata Lyrio Rafael, et al.
Publicado: (2017)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level
por: Chen, Jiahao, et al.
Publicado: (2018)

Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome
por: Tanaka, Yasuhiro, et al.
Publicado: (2017)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Editorial: Uncovering the relationship between myelodysplastic syndromes and acute myeloid leukemia
por: Yassin, Mohamed A., et al.
Publicado: (2023)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

Enhanced Osteogenic Activity and Bone Repair Ability of PLGA/MBG Scaffolds Doped with ZIF-8 Nanoparticles Loaded with BMP-2
por: Ma, Rui, et al.
Publicado: (2023)

Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia
por: Wong, Justin J-L, et al.
Publicado: (2014)

Circular RNAs in Hematopoiesis with a Focus on Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Dostalova Merkerova, Michaela, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia
por: Liu, Ming, et al.
Publicado: (2021)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2021)

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Barakos, Georgios Petros, et al.
Publicado: (2022)

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Zavras, Phaedon D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ub032c6ndnefqfg20nep34l9ob